The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Growth factor involvement in progression of prostate cancer
Abstract
Understanding how the regulation of growth factor pathways alters during prostate cancer (PC) progression may enable researchers to develop targeted therapeutic strategies for advanced disease. PC progression involves the shifting of cells from androgen-dependent growth to an androgen-independent state, sometimes with the loss or mutation of the androgen receptors in PC cells. Both autocrine and paracrine pathways are up-regulated in androgen-independent tumors and may replace androgens as primary growth stimulatory factors in cancer progression. Our discussion focuses on growth factor families that maintain homeostasis between epithelial and stromal cells in the normal prostate and that undergo changes as PC progresses, often making stromal cells redundant. These growth factors include fibroblast growth factor, insulin-like growth factors, epidermal growth factor, transforming growth factor α, retinoic acid, vitamin D3, and the transforming growth factor β families. We review their role in normal prostate development and in cancer progression, using evidence from clinical specimens and models of PC cell growth.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Transforming Growth Factor‐β: Major Role in Regulation of Extracellular Matrix
ROBERTS, A. B., HEINE, U. I., FLANDERS, K. C., & SPORN, M. B. (1990) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1990.tb17931.x · Cited by 696
Transcriptional activation and nuclear targeting signals of the human androgen receptor.
Simental, J. A., Sar, M., Lane, M. V., French, F. S., & Wilson, E. M. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)52466-2 · Cited by 631
Research works printed but not linked: 227
- 1985, Cancer J Clin, 35, 36, 10.3322/canjclin.35.1.36 · DOI · Paper page
- 1994, Incidence and Mortality, 58
- 1990, Cancer J Clin, 44, 7
- 1986, Lancet, i, 60
- 1995, Urology, 46, 757, 10.1016/S0090-4295(99)80339-2 · DOI
- 1994, Urology, 43, 60, 10.1016/S0090-4295(94)80264-5 · doi:10.1016/s0090-4295(94)80264-5
- 1993, J Urol, 150, 400, 10.1016/S0022-5347(17)35493-9 · doi:10.1016/s0022-5347(17)35493-9
- 1994, N Engl J Med, 330, 242, 10.1056/NEJM199401273300403 · DOI · Paper page
- 1993, Prostate diseases, 28
- 1996, Prostate, 28, 98, 10.1002/(SICI)1097-0045(199602)28:2<98::AID-PROS4>3.0.CO;2-J · DOI · Paper page
- 1992, Campbell’s urology, 221
- 1987, Endocr Rev, 8, 338, 10.1210/edrv-8-3-338 · DOI · Paper page
- 1997, Principles and practice of genitourinary oncology, 367
- 1994, N Engl J Med, 331, 996, 10.1056/NEJM199410133311507 · DOI · Paper page
- 1988, Mol Endocrinol, 2, 1265, 10.1210/mend-2-12-1265 · DOI · Paper page
- 1996, Prostate, 6, 52
- 1991, Cancer Surv, 11, 91
- 1991, Cancer, 67, 3057, 10.1002/1097-0142(19910615)67:12<3057::AID-CNCR2820671221>3.0.CO;2-S · DOI
- 1992, J Urol, 147, 798, 10.1016/S0022-5347(17)37389-5 · DOI
- 1996, J Endocrinol, 151, 1, 10.1677/joe.0.1510001 · DOI
- 1995, N Engl J Med, 332, 1393, 10.1056/NEJM199505253322101 · DOI · Paper page
- 1994, Cancer Res, 54, 2861
- 1990, Biochim Biophys Acta, 1052, 187, 10.1016/0167-4889(90)90075-O · DOI · Paper page
- 1994, Biochem Biophys Res Commun, 198, 74, 10.1006/bbrc.1994.1011 · DOI · Paper page
- 1990, Mol Endocrinol, 4, 7211
- 1991, J Biol Chem, 226, 510
- 1994, Cancer Res, 54, 5474
- 1988, Mol Cell Endocrinol, 60, 101, 10.1016/0303-7207(88)90124-4 · doi:10.1016/0303-7207(88)90124-4
- 1996, Prostate, 28, 219, 10.1002/(SICI)1097-0045(199604)28:4<219::AID-PROS2>3.0.CO;2-8 · doi:10.1002/(sici)1097-0045(199604)28:4<219::aid-pros2>3.0.co;2-8
- 1995, Microsc Res Tech, 30, 333, 10.1002/jemt.1070300408 · doi:10.1002/jemt.1070300408
- 1996, Int J Cancer, 67, 573, 10.1002/(SICI)1097-0215(19960807)67:4<573::AID-IJC17>3.0.CO;2-8 · doi:10.1002/(sici)1097-0215(19960807)67:4<573::aid-ijc17>3.0.co;2-8
- 1990, Cancer Res, 90, 3748
- 1985, Cancer Surv, 4, 683
- 1993, Hum Pathol, 24, 4, 10.1016/0046-8177(93)90055-L · DOI · Paper page
- 1996, Urol Oncol, 2, 131, 10.1016/S1078-1439(96)00078-6 · DOI
- 1991, Mol Endocrinol, 5, 503, 10.1210/mend-5-4-503 · doi:10.1210/mend-5-4-503
- 1996, Cancer Res, 56, 3359
- 1992, Mol Endocrinol, 6, 15
- 1996, Cancer Res, 56, 44
- 1996, Clin Cancer Res, 2, 1255
- 1995, Urol Oncol, 1, 252, 10.1016/1078-1439(96)00028-2 · DOI
- 1988, FASEB J, 2, A875
- 1995, Acta Pathol Microbiol Immunol Scand, 103, 140, 10.1111/j.1699-0463.1995.tb01089.x · DOI
- 1992, Endocrinology, 130, 2955, 10.1210/endo.130.5.1374018 · DOI
- 1989, Prostate, 15, 355, 10.1002/pros.2990150408 · doi:10.1002/pros.2990150408
- 1992, Cancer Res, 52, 571
- 1993, Mol Cell Biol, 13, 4513, 10.1128/MCB.13.8.4513 · DOI · Paper page
- 1990, EMBO J, 9, 907, 10.1002/j.1460-2075.1990.tb08188.x · DOI · Paper page
- 1990, J Natl Cancer Inst, 82, 4, 10.1093/jnci/82.1.4 · DOI · Paper page
- 1989, Cancer Res, 49, 2485
- 1991, Cancer Surv, 11, 165
- 1992, Mol Endocrinol, 6, 2123
- 1992, Proc Natl Acad Sci U S A, 89, 3305, 10.1073/pnas.89.8.3305 · DOI
- 1995, Exp Mol Pathol, 63, 52, 10.1006/exmp.1995.1030 · doi:10.1006/exmp.1995.1030
- 1997, Oncogene, 15, 1115, 10.1038/sj.onc.1201256 · doi:10.1038/sj.onc.1201256
- 1996, J Steroid Biochem Mol Biol, 57, 173, 10.1016/0960-0760(95)00259-6 · doi:10.1016/0960-0760(95)00259-6
- 1991, J Clin Endocrinol Metab, 73, 401, 10.1210/jcem-73-2-401 · DOI · Paper page
- 1996, J Clin Endocrinol Metab, 81, 612
- 1996, Int J Urol, 3, 39, 10.1111/j.1442-2042.1996.tb00628.x · DOI
- 1993, J Clin Endocrinol Metab, 77, 229
- 1995, Endocrinology, 136, 1040, 10.1210/endo.136.3.7532576 · DOI
- 1996, Eur J Endocrinol, 134, 591, 10.1530/eje.0.1340591 · DOI
- 1986, Clin Sci, 70, 359, 10.1042/cs0700359 · doi:10.1042/cs0700359
- 1988, Mol Cell Endocrinol, 56, 21, 10.1016/0303-7207(88)90004-4 · DOI
- 1988, Biochem Int, 17, 311
- 1996, Prostate, 28, 139, 10.1002/(SICI)1097-0045(199603)28:3<139::AID-PROS1>3.0.CO;2-A · doi:10.1002/(sici)1097-0045(199603)28:3<139::aid-pros1>3.0.co;2-a
- 1988, J Urol, 139, 857, 10.1016/S0022-5347(17)42662-0 · doi:10.1016/s0022-5347(17)42662-0
- 1993, Br J Cancer, 67, 152, 10.1038/bjc.1993.26 · doi:10.1038/bjc.1993.26
- 1993, Prostate, 23, 9, 10.1002/pros.2990230103 · doi:10.1002/pros.2990230103
- 1996, Hum Pathol, 27, 688, 10.1016/S0046-8177(96)90399-8 · DOI
- 1994, J Urol, 152, 2120, 10.1016/S0022-5347(17)32335-2 · DOI
- 1994, Prostate, 24, 46, 10.1002/pros.2990240110 · DOI
- 1996, Int J Urol, 3, 39, 10.1111/j.1442-2042.1996.tb00628.x · DOI
- 1994, Prostate, 24, 204, 10.1002/pros.2990240406 · DOI
- 1992, J Urol, 147, 1444, 10.1016/S0022-5347(17)37590-0 · DOI
- 1992, Cancer Res, 52, 5403
- 1995, Urology, 45, 542, 10.1016/S0090-4295(99)80034-X · DOI · Paper page
- 1994, J Urol, 151, 1396, 10.1016/S0022-5347(17)35267-9 · DOI
- 1980, Prog Clin Biol Res, 37, 379
- 1963, Natl Cancer Inst Monogr, 12, 351
- 1987, Current approaches to the study of prostate cancer, 513
- 1975, Cancer Res, 35, 1840
- 1986, Prostate, 9, 261, 10.1002/pros.2990090306 · DOI · Paper page
- 1975, Cancer Res, 35, 2935
- 1977, Cancer Res, 37, 1929
- 1980, Prog Clin Biol Res, 37, 325
- 1985, Anticancer Res, 5, 193
- 1989, Int J Cancer, 43, 1179, 10.1002/ijc.2910430636 · DOI
- 1973, J Natl Cancer Inst, 51, 1235, 10.1093/jnci/51.4.1235 · doi:10.1093/jnci/51.4.1235
- 1985, Prostate, 6, 389, 10.1002/pros.2990060407 · doi:10.1002/pros.2990060407
- 1994, Cancer Res, 54, 626
- 1975, J Natl Cancer Inst, 55, 177, 10.1093/jnci/55.1.177 · doi:10.1093/jnci/55.1.177
- 1981, J Natl Cancer Inst, 66, 565
- 1964, Cancer Res, 25, 1168
- 1972, Biochem J, 127, 561, 10.1042/bj1270561 · doi:10.1042/bj1270561
- 1989, Cell, 56, 917, 10.1016/0092-8674(89)90625-9 · DOI · Paper page
- 1983, Tissue Antigens, 21, 227, 10.1111/j.1399-0039.1983.tb00162.x · doi:10.1111/j.1399-0039.1983.tb00162.x
- 1979, Invest Urol, 17, 16
- 1977, Cancer Res, 37, 4049
- 1980, Prog Clin Biol Res, 37, 115
- 1994, Int J Cancer, 57, 406, 10.1002/ijc.2910570319 · DOI · Paper page
- 1994, Cancer Res, 54, 2577
- 1996, Proc Natl Acad Sci U S A, 93, 11802, 10.1073/pnas.93.21.11802 · DOI · Paper page
- 1996, Cancer Res, 56, 3042
- 1980, Prostate, 1, 95, 10.1002/pros.2990010113 · DOI
- 1993, Prostate, 23, 149, 10.1002/pros.2990230208 · doi:10.1002/pros.2990230208
- 1984, J Urol, 132, 384, 10.1016/S0022-5347(17)49633-9 · DOI
- 1996, Int J Cancer, 67, 785, 10.1002/(SICI)1097-0215(19960917)67:6<785::AID-IJC6>3.0.CO;2-N · doi:10.1002/(sici)1097-0215(19960917)67:6<785::aid-ijc6>3.0.co;2-n
- 1987, Cancer Genet Cytogenet, 26, 165, 10.1016/0165-4608(87)90143-9 · doi:10.1016/0165-4608(87)90143-9
- 1988, Mol Cell Endocrinol, 55, 167, 10.1016/0303-7207(88)90131-1 · doi:10.1016/0303-7207(88)90131-1
- 1983, J Cell Biol, 96, 1662, 10.1083/jcb.96.6.1662 · DOI · Paper page
- 1990, J Steroid Biochem Mol Biol, 37, 843, 10.1016/0960-0760(90)90430-S · doi:10.1016/0960-0760(90)90430-s
- 1987, J Urol, 137, 1304, 10.1016/S0022-5347(17)44488-0 · DOI
- 1996, Clin Cancer Res, 2, 1627
- 1991, Cancer Res, 51, 3753
- 1992, J Urol, 147, 1151, 10.1016/S0022-5347(17)37506-7 · DOI · Paper page
- 1991, Cancer Surv, 11, 91
- 1993, Cancer Res, 53, 2852
- 1992, Endocrinology, 131, 3045, 10.1210/endo.131.6.1446639 · doi:10.1210/endo.131.6.1446639
- 1990, Cell, 61, 1121, 10.1016/0092-8674(90)90075-P · DOI · Paper page
- 1995, Proc Natl Acad Sci U S A, 92, 3439, 10.1073/pnas.92.8.3439 · DOI · Paper page
- 1996, Cancer Res, 56, 4894
- 1996, Cancer Res, 56, 4096
- 1990, Peptide growth factors and their receptors: handbook of experimental pharmacology. Volume 95–1, 419
- 1994, World J Urol, 12, 96
- 1989, Mol Endocrinol, 3, 1977, 10.1210/mend-3-12-1977 · DOI · Paper page
- 1990, Ann N Y Acad Sci, 593, 208, 10.1111/j.1749-6632.1990.tb16113.x · DOI
- 1993, Science, 260, 1335, 10.1126/science.8388126 · DOI · Paper page
- 1994, J Biol Chem, 269, 30688, 10.1016/S0021-9258(18)43868-9 · DOI
- 1995, Eur J Clin Invest, 25, 959, 10.1111/j.1365-2362.1995.tb01974.x · DOI
- 1997, Int J Hematol, 65, 97, 10.1016/S0925-5710(96)00542-7 · doi:10.1016/s0925-5710(96)00542-7
- 1990, J Biol Chem, 265, 21393, 10.1016/S0021-9258(18)45745-6 · DOI · Paper page
- 1990, J Biol Chem, 265, 7709, 10.1016/S0021-9258(19)38983-5 · DOI · Paper page
- 1984, Nature, 309, 418, 10.1038/309418a0 · DOI · Paper page
- 1991, Growth Factors, 4, 265, 10.3109/08977199109043912 · DOI · Paper page
- 1990, J Cell Physiol, 144, 108, 10.1002/jcp.1041440114 · DOI · Paper page
- 1990, Cancer Metastasis Rev, 9, 227, 10.1007/BF00046362 · DOI
- 1985, Science, 230, 1385, 10.1126/science.4071057 · DOI · Paper page
- 1991, In Vitro Cell Dev Biol, 27A, 437
- 1989, Science, 245, 752, 10.1126/science.2475908 · DOI · Paper page
- 1989, Endocr Rev, 10, 68, 10.1210/edrv-10-1-68 · DOI · Paper page
- 1989, Cell, 59, 235, 10.1016/0092-8674(89)90281-X · DOI · Paper page
- 1990, Recent Prog Horm Res, 46, 99
- 1991, Cancer Surv, 11, 147
- 1988, EMBO J, 7, 3737, 10.1002/j.1460-2075.1988.tb03257.x · DOI · Paper page
- 1989, EMBO J, 6, 1899
- 1990, Cell, 53, 515
- 1990, Cell, 62, 175, 10.1016/0092-8674(90)90251-9 · DOI · Paper page
- 1991, EMBO J, 10, 1091, 10.1002/j.1460-2075.1991.tb08049.x · DOI · Paper page
- 1993, Cancer Res, 53, 3193
- 1989, Mol Cell Endocrinol, 62, 79, 10.1016/0303-7207(89)90115-9 · doi:10.1016/0303-7207(89)90115-9
- 1987, Biochemistry, 26, 2406, 10.1021/bi00383a002 · doi:10.1021/bi00383a002
- 1989, Mol Cell Biol, 9, 5508, 10.1128/MCB.9.12.5508 · DOI · Paper page
- 1997, Clin Exp Metastasis, 15, 41
- 1984, Cancer Res, 44, 1998
- 1989, Growth Factors, 1, 237
- 1989, Urol Int, 44, 71, 10.1159/000281473 · doi:10.1159/000281473
- 1992, J Cell Biochem Suppl, 16, 99
- 1992, Cancer Res, 33, 1651
- 1990, Prostate, 16, 209, 10.1002/pros.2990160304 · DOI
- 1989, Prostate, 15, 177, 10.1002/pros.2990150211 · DOI
- 1992, Br J Cancer, 65, 177, 10.1038/bjc.1992.37 · doi:10.1038/bjc.1992.37
- 1993, Mol Cell Biochem, 126, 151, 10.1007/BF00925693 · DOI
- 1994, Steroids, 59, 412, 10.1016/0039-128X(94)90010-8 · doi:10.1016/0039-128x(94)90010-8
- 1994, Surg Oncol, 3, 237, 10.1016/0960-7404(94)90039-6 · doi:10.1016/0960-7404(94)90039-6
- 1992, Br J Cancer, 65, 177, 10.1038/bjc.1992.37 · doi:10.1038/bjc.1992.37
- 1994, Br J Urol, 74, 214, 10.1111/j.1464-410X.1994.tb16589.x · doi:10.1111/j.1464-410x.1994.tb16589.x
- 1994, Prostate, 25, 199, 10.1002/pros.2990250405 · doi:10.1002/pros.2990250405
- 1990, J Urol, 143, 1272, 10.1016/S0022-5347(17)40253-9 · DOI
- 1991, J Steroid Biochem Mol Biol, 40, 199, 10.1016/0960-0760(91)90183-6 · doi:10.1016/0960-0760(91)90183-6
- 1991, J Steroid Biochem Mol Biol, 40, 193, 10.1016/0960-0760(91)90182-5 · DOI
- 1996, Prostate, 28, 392, 10.1002/(SICI)1097-0045(199606)28:6<392::AID-PROS9>3.0.CO;2-C · DOI · Paper page
- 1991, Mol Cell Biol, 11, 4627, 10.1128/MCB.11.9.4627 · DOI · Paper page
- 1992, Mol Cell Biol, 12, 82, 10.1128/MCB.12.1.82 · DOI · Paper page
- 1992, J Neurosci, 12, 142, 10.1523/JNEUROSCI.12-01-00142.1992 · DOI · Paper page
- 1986, EMBO J, 5, 2523, 10.1002/j.1460-2075.1986.tb04530.x · DOI · Paper page
- 1991, Growth Factors, 4, 277, 10.3109/08977199109043913 · DOI
- 1985, Regul Pept, 12, 201, 10.1016/0167-0115(85)90061-8 · DOI
- 1987, Nature, 325, 257, 10.1038/325257a0 · DOI · Paper page
- 1987, Nature, 326, 197, 10.1038/326197a0 · DOI · Paper page
- 1987, Curr Eye Res, 6, 1165, 10.3109/02713688709034890 · doi:10.3109/02713688709034890
- 1987, J Cell Biol, 104, 635, 10.1083/jcb.104.3.635 · DOI · Paper page
- 1996, Prostate, 28, 352, 10.1002/(SICI)1097-0045(199606)28:6<352::AID-PROS3>3.0.CO;2-C · doi:10.1002/(sici)1097-0045(199606)28:6<352::aid-pros3>3.0.co;2-c
- 1993, Prostate, 22, 183, 10.1002/pros.2990220302 · DOI
- 1989, Cancer Res, 49, 5889
- 1992, J Steroid Biochem Mol Biol, 41, 659, 10.1016/0960-0760(92)90400-D · doi:10.1016/0960-0760(92)90400-d
- 1994, Prostate, 25, 206, 10.1002/pros.2990250406 · doi:10.1002/pros.2990250406
- 1993, Jpn J Cancer Res, 84, 1300, 10.1111/j.1349-7006.1993.tb02838.x · doi:10.1111/j.1349-7006.1993.tb02838.x
- 1993, Am J Pathol, 43, 401
- 1983, Cancer, 53, 246
- 1996, Int J Dev Biol, 40, 941
- 1994, Growth Factors, 10, 269, 10.3109/08977199409010993 · DOI
- 1996, Growth Regul, 6, 22
- 1993, Cancer Res, 53, 1102
- 1993, Prostate, 22, 243, 10.1002/pros.2990220307 · DOI · Paper page
- 1996, Endocrinology, 137, 2676, 10.1210/endo.137.7.8770886 · doi:10.1210/endo.137.7.8770886
- 1995, J Bone Miner Res, 10, 788, 10.1002/jbmr.5650100516 · doi:10.1002/jbmr.5650100516
- 1987, Nutr Cancer, 9, 123, 10.1080/01635588709513919 · DOI
- 1992, Mol Biol Cell, 3, 189, 10.1091/mbc.3.2.189 · DOI
- 1989, Cell Regul, 1, 87, 10.1091/mbc.1.1.87 · DOI · Paper page
200 of 227 shown
Cited by
Stromal fibroblasts in cancer initiation and progression
Bhowmick, N. A., Neilson, E. G., & Moses, H. L. (2004) · Nature · doi:10.1038/nature03096 · Cited by 2,302
Androgen Receptor in Prostate Cancer
Heinlein, C. A., & Chang, C. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0032 · Cited by 1,780
Androgen Receptor (AR) Coregulators: An Overview
Heinlein, C. A., & Chang, C. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.2.0460 · Cited by 943
Androgen Receptor Signaling in Androgen-Refractory Prostate Cancer
Grossmann, M. E., Huang, H., & Tindall, D. J. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.22.1687 · Cited by 548
Bhowmick, N. A., & Moses, H. L. (2005) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2004.12.003 · Cited by 441
Gan, R.-Y., Li, H.-B., Sui, Z.-Q., & Corke, H. (2018) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2016.1231168 · Cited by 438
Graff, J. R., Konicek, B. W., McNulty, A. M., Wang, Z., Houck, K., Allen, S., Paul, J. D., Hbaiu, A., Goode, R. G., Sandusky, G. E., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003145200 · Cited by 378
Androgen deprivation therapy for prostate cancer: Current status and future prospects
Miyamoto, H., Messing, E. M., & Chang, C. (2004) · The Prostate · doi:10.1002/pros.20115 · Cited by 317
Molecular cell biology of androgen receptor signalling
Bennett, N. C., Gardiner, R. A., Hooper, J. D., Johnson, D. W., & Gobe, G. C. (2010) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2009.11.013 · Cited by 292
Androgen receptor and growth factor signaling cross-talk in prostate cancer cells.
Zhu, M.-L., & Kyprianou, N. (2008) · Endocrine Related Cancer · doi:10.1677/erc-08-0084 · Cited by 286
“EGF and its membrane receptor, the epidermal growth factor-1 receptor (EGFR), are involved in the pathogenesis of different tumors, including prostate cancer (Russell et al. 1998).”
BackgroundMurillo, H. (2001) · Endocrinology · doi:10.1210/en.142.11.4795 · Cited by 263
(2002) · PubMed · Cited by 175
Yuan, T. T.-T., Toy, P., McClary, J. A., Lin, R. J., Miyamoto, N. G., & Kretschmer, P. J. (2001) · Gene · doi:10.1016/s0378-1119(01)00709-0 · Cited by 66
Tgf-beta in the natural history of prostate cancer
Ahel, J. (2019) · Acta Clinica Croatica · doi:10.20471/acc.2019.58.01.17 · Cited by 30
Metadata
- Authors
- Russell, P. J., Bennett, S., & Stricker, P.
- Venue
- Clinical Chemistry
- Publisher
- Oxford University Press (OUP)
- Published
- 1998-04-01
- Volume
- 44
- Issue
- 4
- Pages
- 705-723
- ISSN
- 0009-9147 (ISSN-L)
- 1530-8561
- OpenAlex
- W4298355764
- Cited by
- 216
- References
- 2
- FWCI
- 14.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.